Home › Interstitial Lung Diseases › New York
Interstitial Lung Diseases clinical trials in New York
20 studies for Interstitial Lung Diseases are looking for participants at sites in New York.
Cities in New York
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- Weill Cornell Medicine-New York-60569, New York
- Columbia University Medical Center-New York Presbyterian Hospital, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07540988A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- Weill Cornell Medicine-New York-60569, New York
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 30, 2026 · NCT07201922Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- USA005, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07179380LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medicine, New York
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), East White Plains
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07323732A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- GSK Investigational Site, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06716606A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- GSK Investigational Site, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Buffalo, Buffalo
- Weill Cornell University Medical College, New York
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- NYU Langone Health, New York
- University of Rochester Medical Center, Rochester
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 2, 2026 · NCT07285655DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Northwell Health, New Hyde Park
- New York University Langone Medical Center, New York
- New York Presbyterian Hospital - Weill Cornell Medicine, New York
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- Weill Cornell Medicine, New York
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Aug 18, 2026 · NCT06855329Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Weill Medical College of Cornell University, New York
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease
- University of Rochester Medical Center, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07561034Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Northwell Health, New Hyde Park
- Weill Cornell Medicine, New York-Presbyterian Hospital, New York
- Stony Brook Advanced Specialty Care, Stony Brook
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535Cough Capture as a Portal Into the Lung
- Albert Einstein College of Medicine, The Bronx
RecruitingObservational study
Ages 21 and older · All sexes · Updated Jan 13, 2026 · NCT05854563Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.